Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712181 | 0.76 | ALDH1A1 (0.44) | L3MBTL1ALDH1A1TP53TSHR | |
| SCHEMBL26628356 | 0.74 | CYP1A2 (0.39) | L3MBTL1ALDH1A1 | |
| SCHEMBL2373214 | 0.73 | — | — | |
| SCHEMBL31734135 | 0.71 | ALDH1A1 (0.39) | L3MBTL1ALDH1A1TP53TSHR | |
| SCHEMBL6969487 | 0.69 | ALDH1A1 (0.37) | L3MBTL1ALDH1A1TP53TSHR | |
| SCHEMBL3136565 | 0.69 | ALDH1A1 (0.44) | L3MBTL1ALDH1A1TP53TSHR | |
| SCHEMBL28207990 | 0.67 | OR51E2 (0.30) | — | |
| SCHEMBL1563693 | 0.67 | CRBN (0.41) | L3MBTL1ALDH1A1TP53TSHR | |
| SCHEMBL4948924 | 0.67 | — | — | |
| SCHEMBL7937203 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107709343-B | Vaccine against streptococcus pneumoniae serotype 5 | 马克斯·普朗克科学促进学会 | 2021-05-18 | — | — | CN | disclosed |
| EP-3303357-B1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 5 | MAX PLANCK GESELLSCHAFT (DE) | 2021-05-12 | — | — | EP | disclosed |
| US-10596272-B2 | Vaccines against Streptococcus pneumoniae serotype 5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-03-24 | — | — | US | disclosed |
| US-20180296687-A1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2018-10-18 | — | — | US | disclosed |
| EP-3303357-A1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 5 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften (DE) | 2018-04-11 | — | — | EP | disclosed |
| CN-107709343-A | Vaccine against Streptococcus pneumoniae serotype 5 | 马克斯·普朗克科学促进学会 | 2018-02-16 | — | — | CN | disclosed |
| WO-2016198170-A1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-12-15 | — | — | WO | disclosed |
| EP-0865283-A4 | 2-DEOXYSTREPTAMINE AS A MOLECULAR SCAFFOLD FOR PREPARING FUNCTIONALLY AND SPACIALLY DIVERSE MOLECULES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6140361-A | FOR INHIBITING BINDING OF HUMAN IMMUNODEFICIENCY VIRUS REV PROTEIN TO REV RESPONSIVE ELEMENTS (RRE) | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-5942547-A | FOR INHIBITING BINDING OF HUMAN IMMUNODEFICIENCY VIRUS PROTEIN TO RESPONSIVE ELEMENT; TREATMENT OF AIDS | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0865283-A1 | 2-DEOXYSTREPTAMINE AS A MOLECULAR SCAFFOLD FOR PREPARING FUNCTIONALLY AND SPACIALLY DIVERSE MOLECULES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Scriptgen Pharmaceuticals Inc. (US) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997009053-A9 | 2-DEOXYSTREPTAMINE AS A MOLECULAR SCAFFOLD FOR PREPARING FUNCTIONALLY AND SPATIALLY DIVERSE MOLECULES AND PHARMACEUTICAL COMPOSITIONS THEREOF | — | 1997-05-01 | — | — | WO | disclosed |
| WO-1997009053-A1 | 2-DEOXYSTREPTAMINE AS A MOLECULAR SCAFFOLD FOR PREPARING FUNCTIONALLY AND SPATIALLY DIVERSE MOLECULES AND PHARMACEUTICAL COMPOSITIONS THEREOF | SCRIPTGEN PHARMACEUTICALS, INC. (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296687-A1 | VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 5 | FUT5, SPAG5, IL5 | L3MBTL1 3234/4885ALDH1A1 3515/4885TP53 953/4885 |
| US-10596272-B2 | Vaccines against Streptococcus pneumoniae serotype 5 | FUT5, SPAG5, IL5 | L3MBTL1 3234/4885ALDH1A1 3515/4885TP53 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.